DJIA 18,126.12 -36.87 -0.20%
NASDAQ 5,097.98 -8.62 -0.17%
S&P 500 2,120.79 -2.69 -0.13%
market minute promo

Merck & Co., Inc. (NYSE: MRK)

59.70 0.24 (0.40%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

MRK $59.70 0.40%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $59.45
Previous Close $59.46
Daily Range $59.38 - $59.85
52-Week Range $52.49 - $63.62
Market Cap $168.7B
P/E Ratio 15.52
Dividend (Yield) $1.80 (3.0%)
Ex-Dividend Date
Dividend Pay Date
06/11/15
07/08/15
Volume 9,530,115
Average Daily Volume 10,475,186
Current FY EPS $3.43

Sector

Healthcare

Industry

Drug Makers

Merck & Co., Inc. (MRK) Description

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health. Website: http://www.merck.com/

News & Commentary Rss Feed

Gilead's Sustainable Competitive Advantage

Gilead Sciences' long-term growth is being doubted by the Street because of the uncertainty surrounding the hep C market going forward. The biotech's top notch CEO John Martin, however, should be reason enough for investors to believe that company's best days lie ahead. Here's why.

Is A Big Acquisition Is Due For Pfizer?

Short Sellers More Selective on Big Pharma Stocks

Merck/J&J Get CHMP Backing for Simponi's Expanded Use - Analyst Blog

Merck/J&J Get CHMP Backing for Simponi's Expanded Use - Analyst Blog

Cancer Drug Spending Breaks Through $100B With Immunotherapy Still In Its Infancy

Daily Dividend Report: MRK, DE, ESS, STR, DSW, MOV

Abbvie Inc. Dividend Stock Analysis

Merck's (MRK) Keytruda a Step Closer to European Approval - Analyst Blog

Merck's (MRK) Keytruda a Step Closer to European Approval - Analyst Blog

10% Upside If J&J Is Even Partially Successful In Its R&D Plan

See More MRK News...

MRK's Top Competitors

MRK $59.70 (0.40%)
Current stock: MRK
RHHBY $37.40 (1.38%)
Current stock: RHHBY
JNJ $101.15 (0.02%)
Current stock: JNJ
PFE $34.44 (0.41%)
Current stock: PFE